Changes in total IgE levels predict pulmonary outcome in cystic fibrosis related allergic bronchopulmonary aspergillosis

Florian Gothe (Munich, Germany), Florian Gothe, Matthias Kappler, Matthias Griese

Source: International Congress 2016 – Cystic fibrosis: various aspects
Session: Cystic fibrosis: various aspects
Session type: Thematic Poster
Number: 1259
Disease area: Paediatric lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Florian Gothe (Munich, Germany), Florian Gothe, Matthias Kappler, Matthias Griese. Changes in total IgE levels predict pulmonary outcome in cystic fibrosis related allergic bronchopulmonary aspergillosis. Eur Respir J 2016; 48: Suppl. 60, 1259

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Vitamin D level in cystic fibrosis patients with allergic bronchopulmonary aspergillosis and aspergillus sensitization
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults
Year: 2013


Steroid sparing effect of anti-IgE antibody in allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children
Year: 2013


The efficacity of omaluzimab in a case series with allergic bronchopulmonary aspergillosis and cystic fibrosis
Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment
Year: 2015


Omalizumab for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in children with cystic fibrosis (CF)
Source: International Congress 2014 – Cystic fibrosis: clinical assessment and treatment
Year: 2014


Risk factors for allergic bronchopulmonary aspergillosis in paediatric patients with cystic fibrosis
Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more
Year: 2010

Long term follow up of the lung function in cystic fibrosis patients with allergic bronchopulmonary aspergillosis (ABPA)
Source: Annual Congress 2009 - Cystic fibrosis: understanding a complex disease
Year: 2009


Bronchodilator responsiveness in children with cystic fibrosis and allergic bronchopulmonary aspergillosis
Source: Eur Respir J, 56 (2) 2000175; 10.1183/13993003.00175-2020
Year: 2020



A new risk factor predicts ABPA in patients with cystic fibrosis
Source: International Congress 2015 – Cystic fibrosis: assessment and treatment
Year: 2015

Comparison of serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis
Source: Eur Respir J 2008; 31: 36-42
Year: 2008



Early detection of pulmonary exacerbations in children with cystic fibrosis by electronic home monitoring of symptoms and lung function
Source: International Congress 2016 – Cystic fibrosis: monitoring and management
Year: 2016


Allergic bronchopulmonary aspergillosis in cystic fibrosis
Source: Annual Congress 2009 - Update on eosinophilic lung diseases
Year: 2009


Allergic bronchopulmonary aspergillosis in cystic fibrosis
Source: Eur Respir J 2001; 17: 156
Year: 2001


Allergic bronchopulmonary aspergillosis in cystic fibrosis
Source: Eur Respir J 2001; 17: 1052-1053
Year: 2001


Vitamin D serum level and pulmonary exacerbations in children with cystic fibrosis
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children
Year: 2013


Blood basophil activation is a reliable biomarker of allergic bronchopulmonary aspergillosis in cystic fibrosis
Source: Eur Respir J 2016; 47: 177-185
Year: 2016



Lung clearance index during pulmonary exacerbation in school-age children with cystic fibrosis
Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children
Year: 2013


Effects and side effects of long term steroid therapy of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis
Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more
Year: 2010


Differences in clinical features and biomarkers of subsequent acute cystic fibrosis pulmonary exacerbations - Analysing exacerbations as separate entities
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults
Year: 2013


Surfactant protein D in serum from patients with allergic bronchopulmonary aspergillosis
Source: Eur Respir J 2003 Oct 01;22(4):592-595
Year: 2003



Changes in pulmonary function tests following antibiotics in infants with pulmonary exacerbation of cystic fibrosis
Source: Annual Congress 2013 –Cystic fibrosis: lung function and change of lung function in infants and children before and after treatment
Year: 2013